SCHEMBL8389283

SCHEMBL8389283

CC(C)c1ccc(C(F)(F)F)cc1Br

nearest known ligand 0.49

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PDE2A O00408 6/20 0.49
HTR2A P28223 2/20 0.37
HTR2C P28335 1/20 0.37
HTR2B P41595 1/20 0.37
ALDH1A1 P00352 1/20 0.35
HSP90AA1 P07900 1/20 0.35
HSP90AB1 P08238 1/20 0.35
PTPN5 P54829 1/20 0.34
KIF11 P52732 2/20 0.34
GABRA1 P14867 1/20 0.33
GABRB1 P18505 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
CES2 O00748 1/20 0.33
SLC6A4 P31645 1/20 0.33
KCNH2 Q12809 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27877627 0.86 PDE2A (0.47) PDE2AHTR2AHTR2CHTR2BALDH1A1
SCHEMBL31704883 0.85 PDE2A (0.46) PDE2AHTR2AHTR2CHTR2BALDH1A1
SCHEMBL31706720 0.85 PDE2A (0.46) PDE2AHTR2AHTR2CHTR2BALDH1A1
SCHEMBL27850851 0.85 PDE2A (0.64) PDE2AHTR2AHTR2CHTR2BALDH1A1
SCHEMBL2481758 0.85 PDE2A (0.64) PDE2AHTR2AHTR2CHTR2BALDH1A1
SCHEMBL22747383 0.84 PDE2A (0.44) PDE2AHTR2AHTR2CHTR2BALDH1A1
SCHEMBL12889906 0.81 PDE2A (0.53) PDE2AHTR2AHTR2CHTR2BALDH1A1
SCHEMBL25358453 0.79 PDE2A (0.41) PDE2APTPN5KIF11NPSR1
SCHEMBL10304787 0.79 PDE2A (0.52) PDE2AHTR2AHTR2CHTR2BALDH1A1
SCHEMBL8291096 0.78 PDE2A (0.50) PDE2AHTR2AHTR2CHTR2BALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070149557-A1 CXCR3 antagonists AMGEN INC. (US) 2007-06-28 US disclosed
US-5877191-A ANTIINFLAMMATORY AGENT; ANALGESICS; ANTIHISTAMINES; EMESIS MERCK & CO., INC. (US) 1999-03-02 US disclosed
WO-1998017660-A1 PHENYL SPIROETHERCYCLOALKYL TACHYKININ RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 1998-04-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070149557-A1 CXCR3 antagonists CXCR3, CXCR1, CCR5 PDE2A 2737/4885HTR2A 2430/4885HTR2C 2864/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.